Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA of neuroblastomas tumoroids treated, or not, with ether JQ1 or retinoic acid

ABSTRACT: A GRN inference algorithm identified the KO of TCF4 as an important dynamical player in neuroblastomas tumoroids. JQ1 treatment is supposed to mimic in silico the KO of TCF4. Retinoic acid is supposed to induce forced differentiation of neuroblastomas.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens

SUBMITTER: Olivier Gandrillon

PROVIDER: E-MTAB-16963 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

scRNAseq dataset from neuroblastomas tumoroids

Project description:Neuroblastoma (NB), a pediatric cancer arising from disrupted sympathetic neuron differentiation, exhibits marked heterogeneity and limited therapeutic options. To better understand its molecular circuitry dynamics, we applied CARDAMOM, a novel Gene Regulatory Network (GRN) inference framework to single-cell RNA-seq data from patient-derived tumoroids. This approach models gene regulation via piecewise deterministic Markov processes, capturing transcriptional bursting and protein-mediated feedback, overcoming limitations of RNA velocity (e.g., gene independence and lack of biological time). We identified a continuous chromaffin-to-sympathoblast differentiation trajectory, validated by RNA velocity and scFates. Using velocity pseudotime, we selected 85 dynamically relevant genes enriched in cell cycle and DNA replication functions. Notably, 9 genes overlapped with those driving normal sympathoadrenal differentiation, underscoring tumor-normal similarity. The inferred 85-genes network reproduced quite well experimental gene expression patterns in silico, and allowed to predict protein-level dynamics. Furthermore, it allowed to assess the effect of in silico perturbations (both knock-out and overexpression) of hub genes (e.g., TCF4 and PLK1). We show that those perturbations significantly altered cell fate proportions, with TCF4 knockout increasing chromaffin-like cells and reducing proliferative late sympathoblasts — suggesting a therapeutic strategy to promote differentiation. Our work therefore demonstrates that NB tumoroids retain a dynamic, differentiation-like architecture amenable to GRN modeling. Predicted druggable targets (e.g., PLK1, TCF4) offer testable therapeutic avenues, including repurposing BET inhibitors (JQ1) or PLK1 inhibitors (BI2536), potentially in combination.

2026-07-07 | E-MTAB-16741 | biostudies-arrayexpress

scRNAseq dataset from neuroblastomas tumoroids

Project description:scRNAseq dataset from neuroblastomas tumoroids

| PRJEB109955 | ENA

scRNA of neuroblastomas tumoroids treated, or not, with ether JQ1 or retinoic acid

Project description:scRNA of neuroblastomas tumoroids treated, or not, with ether JQ1 or retinoic acid

| PRJEB112100 | ENA

Differentation in neuroblastomas

Project description:Expression profiling according to differentiation was analysed in 34 neuroblastomas

2009-02-20 | GSE14880 | GEO

DNA methylation data from 58 primary neuroblastomas

Project description:Genome wide DNA methylation profiling of primary neuroblastomas. The Illumina 450k methylation array was used to obtain DNA methylation profiles across approximately 485,000 CpGs in 58 neuroblastomas. Data were analyzed with regard to differential methylation at ATRX and DAXX loci in relation to genomic MYCN, TERT and ATRX status, presence of alternative lengthening of telomeres (ALT) and TERT expression. The analysis is part of the study: A mechanistic classification of clinical phenotypes in neuroblastoma (Ackermann et al., 2018)

2018-12-19 | GSE120650 | GEO

DNA methylation data from 58 primary neuroblastomas

Project description:DNA methylation data from 58 primary neuroblastomas

| PRJNA493833 | ENA

Transcription profiling of human normal neuroblasts vs. malignant neuroblastomas (low- and high-stage)

Project description:Comparison of normal neuroblasts with malignant neuroblastomas (low- and high-stage)

2006-12-18 | E-MEXP-669 | biostudies-arrayexpress

Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition [SEQ]

Project description:SNP arrays were combined with next generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas and identify allelic variants in genes relevant for neuroblastoma aetiology. We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in vivo models.

2017-07-28 | GSE101989 | GEO

Expression profiling of murine MYCN-driven neuroblastomas from LSL-MYCN; Dbh-iCre mice.

Project description:Amplification of MYCN is the most prominent genetic marker of high-stage neuroblastoma, a childhood tumor originating from the neural crest. We generated a transgenic mouse with Cre-conditional induction of MYCN in dopamine beta hydroxylase expressing cells that develops murine neuroblastomas.

2014-09-01 | GSE51297 | GEO

Analysis of RNA-seq of human neuroblastomas from mouse-human neural crest chimeric mice model and in other neuroblastoma models

Project description:To confirm the neuroblastomas (NB) identity of human neuroblastomas from mouse-human neural crest chimeric mice model (CHNBs) we characterized their gene expression profiles by RNA-Seq (CHNBs MYCN+ALKF1174L; n=8). For a global comparison of gene expression profiles of CHNBs with other NB models, we further collected RNA-seq data from patient derived xenografts of neuroblastoma (PDX NBs ; MYCNamp+ALKwt PDX; n=2, and MYCNamp+ALKF1174L PDX; n=3), neuroblastomas from genetically engineered mouse model (GEMM NBs; Th-MYCN+ALKF1174L; n=3), neuroblastoma established cell lines (n=2; Kelly, MYCNamp+ALKF1174L; SH-SY5Y, MYCNwt+ ALKF1174L), human pluripotent derived human neural crest cells (hNCCs; wt hNCCs; n=2, and MYCN+ALKF1174L hNCCs, with Dox; n=2) and from hNCC xenografts (MYCN+ALKF1174L; n=5).

2020-01-29 | GSE144366 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data